HealthQuill Cancer
Lupin Pharma
Drugs Health Research

Role of vitamins and diets in cancer prevention, treatment

HQ Team May 15, 2025: A recent meta research by Dr Salvatore Cortellino and Professor Antonio Giordano, President of the Sbarro Health Research Organization (SHRO) and molecular oncologist.

Read More
FDA has granted full approval for Janssen Biotech’s Balversa drug to treat metastatic bladder cancer after clinical trials showed “significant” improvement in overall survival rates.
Uncategorized

Study sees rising cancer cases in young adults; death rates remain stable

HQ Team May 8, 2025: In a surprising and concerning trend, new research from the National Institutes of Health (NIH) reveals that 14 types of cancer are.

Read More
Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new under-the-skin injection version of the cancer therapy, nivolumab (Opdivo), offering a quicker administration option for eligible patients than the currently available drip treatment. 
Drugs Medical Pharma

UK regulator clears subcutaneous injection of Bristol Myers for cancers

HQ Team May 1, 2025: Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new under-the-skin injection version of the cancer.

Read More
IntraBio Inc, a biotechnology company focused on rare and neurodegenerative diseases, got the US regulator’s nod for a drug to treat a certain type of Niemann-Pick disease in adults and pediatric patients weighing about 15 kilograms.
Health

Primary care clinics can help detect 10% of cancers caused by genes

HQ Team March 10, 2025: Patient screening in primary care settings can detect up to 10% of cancers caused by genes. Easily available.

Read More
US scientists have blocked a protein that kills a variety of cancer cells in an experiment on mice, pointing to a new potential target for cancer treatment, according to the National Institutes of Health.
Drugs Health Research

US scientists block proteins that aid cancer cells’ group strategy to survive

HQ Team March 5, 2025: US scientists have blocked a protein that kills a variety of cancer cells in an experiment on mice,.

Read More
FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing the Anglo-Swedish firm to gain access to an anaemia drug in the world’s most populated nation.
Drugs Health Pharma

AstraZeneca Plc buys China unit of FibroGen Inc for $160 million

HQ Team February 21, 2025: FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing.

Read More
Hyundai ADM Bio, a subsidiary of South Korea’s Hyundai Bioscience, unveiled an oral cancer drug that allows patients to make a shift from intravenous chemotherapy.
Health Medical Pharma

South Korea’s Hyundai ADM unveils oral chemotherapy drug

Hyundai ADM Bio, a subsidiary of South Korea’s Hyundai Bioscience, unveiled an oral cancer drug that allows patients to make a shift from intravenous.

Read More
The US drug regulator has put a clinical hold on Atara Biotherapeutics’ T-cell therapies for cancer and autoimmune diseases after issues were observed at a third-party manufacturing facility.
Drugs Health Medical Pharma

FDA places Atara’s Biothearapeutics’ cancer, autoimmune therapies on hold

The US drug regulator has put a clinical hold on Atara Biotherapeutics’ T-cell therapies for cancer and autoimmune diseases after issues were observed.

Read More
Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from the Japanese company.
Drugs Health Pharma

Daiichi Sankyo to buy cancer antibody from Glycotope for $132.5 million

Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from.

Read More
China’s WuXi Biologics, a clinical research organization, has granted global rights to US-based Candid Therapeutics to use the company’s synthetic antibody to fight cancer for an upfront payment of $925 million.
Drugs Medical Pharma

WuXi Biologics sells global rights to cancer antibody to Candid for $925m

China’s WuXi Biologics, a clinical research organization, has granted global rights to US-based Candid Therapeutics to use the company’s synthetic antibody to fight.

Read More